Revoche e sospensioni, ritiri di lotti, farmaci carenti, note di sicurezza, rimborsabilità e nuovi medicinali — ogni giorno, automaticamente. Ultimo aggiornamento: 10/11/2026 08:15.
n. EU/1/26/2062 · Zokovea is indicated for the post exposure prophylaxis of COVID 19 in adults and adolescents aged 12 years and… · Shionogi B.V. · ensitrelvir · ATC J05AE16
n. EU/1/26/2055 · Ubeslo is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or m… · A. Menarini International Licensing S.A. · Obicetrapib · ATC C10AX
n. EU/1/26/2065 · Tafamidis Accord is indicated for the treatment of hereditary transthyretin amyloidosis in adult patients with… · Accord Healthcare S.L.U. · tafamidis · ATC N07XX08
n. EU/1/26/2064 · Myelofibrosis (MF)
Ruxolitinib Viatris is indicated for the treatment of disease-related splenomegaly or … · Viatris Limited · ruxolitinib · ATC L01EJ01
n. EU/1/26/2051 · Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated wi… · QILU PHARMA SPAIN S.L. · pegfilgrastim · ATC L03AA13
n. EU/1/26/2056 · Evlarco is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or … · A. Menarini International Licensing S.A. · obicetrapib / ezetimibe
n. EU/1/25/2006 · autorizzato il 12/02/2026 · Aumseqa as monotherapy is indicated for:
• the first line treatment of adult patients with advanced non small… · SFL Pharmaceuticals Deutschland GmbH · aumolertinib · ATC L01EB11
Elevata richiesta: distribuzione contingentata · equivalente: Sì · 1 FLACONCINO DI POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE DA 500 MG · AIC 036587018 · ELI LILLY NEDERLAND B.V. · PEMETREXED DISODICO · ATC L01BA04
n. EU/1/26/2066 · Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated wi… · CuraTeQ Biologics s.r.o · Pegfilgrastim · ATC L03AA13
n. EU/1/14/941 · autorizzato il 22/08/2014 · This medicinal product is for diagnostic use only.
VIZAMYL is a radiopharmaceutical indicated for Positron Em… · GE Healthcare AS · flutemetamol (18F) · ATC V09AX04
n. EU/1/15/1079 · autorizzato il 15/02/2016 · Vaxelis (DTaP-HB-IPV-Hib) is indicated for primary and booster vaccination in infants and toddlers from the ag… · MCM Vaccine B.V. · Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed) · ATC J07CA09
n. EU/1/16/1135 · autorizzato il 15/09/2016 · Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3… · Proveca Pharma Limited · glycopyrronium bromide · ATC A03AB02
n. EU/1/25/1947 · autorizzato il 28/07/2025 · RIULVY is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing … · Neuraxpharm Pharmaceuticals, S.L. · Tegomil fumarate · ATC L04AX10
n. EU/1/23/1730 · autorizzato il 31/05/2023 · Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with… · Neuraxpharm Pharmaceuticals, S.L. · ublituximab · ATC L04AG14
n. EU/1/25/1957 · autorizzato il 14/08/2025 · Adult Crohn’s Disease
Usymro is indicated for the treatment of adult patients with moderately to severely ac… · Gedeon Richter Plc. · ustekinumab · ATC L04AC05
n. EU/1/10/638 · autorizzato il 27/07/2010 · OZURDEX is indicated for the treatment of adult patients with:
• Visual impairment due to diabetic macular oe… · AbbVie Deutschland GmbH & Co. KG · dexamethasone · ATC S01BA01
n. EU/1/23/1732 · autorizzato il 31/05/2023 · Lacosamide Adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secon… · Extrovis EU Kft. · lacosamide · ATC N03AX18
n. EU/1/15/1064 · autorizzato il 16/12/2015 · Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly me… · Amgen Europe B.V. · talimogene laherparepvec · ATC L01XL02
n. EU/1/25/2006 · autorizzato il 12/02/2026 · Aumseqa as monotherapy is indicated for:
• the first line treatment of adult patients with advanced non small… · SFL Pharmaceuticals Deutschland GmbH · aumolertinib · ATC L01EB11
fine presunta 16/10/2026 · Problemi produttivi · equivalente: No · 1000 UI + 1200 UI/10 ML POLVERE E SOLVENTE PER SOLUZIONE PER INFUSIONE- 1 FLACONCINO POLVERE + 1 SIRINGA PRER CON 10 ML DI SOLV + ACCESSORI · AIC 033866068 · INSTITUTO GRIFOLS S.A. · FATTORE VIII DI COAGULAZIONE DEL SANGUE UMANO LIOFILIZZATO/FATTORE DI VON WILLEBRAND · ATC B02BD06
fine presunta 06/10/2026 · Problemi produttivi: distribuzione contingentata · equivalente: No · 0.75 MG / ML - POLVERE PER SOLUZIONE ORALE - USO GASTROENTERICO, USO ORALE ? FLACONE (VETRO) ? 1 FLACONE + 1 ADATTATORE A PRESSIONE PER FLACONE + 2 SIRINGHE DA 6 ML + 2 SIRINGHE DA 12 ML · AIC 049370012 · ROCHE REGISTRATION GMBH · RISDIPLAM · ATC M09AX10
Lekoskop